and "not recommended," with respective ASCVD event rates of 5.2%, 1.5%, and 1.3% for those with a CAC score of 0, and 15%, 6%, and 9.6% if the Agatston CAC score was $100.
This important study confirms that, in the current era of updated and presumably improved predictive scores (7), CAC retains a strong ability to reclassify cardiovascular risk. In addition, it addresses a critical issue and represents a step in the right direction: in an environment with limited resources, efforts should be made to identify not only newer indications for therapy but also those who may not significantly benefit from it. In the case of statins for primary ASCVD prevention, the absence of CAC may represent such a tool, based on the data presented in this paper and also in Framingham cohorts (7) . The study also raises, among others, several relevant has no relationships relevant to the contents of this paper to disclose. (5) and questions the comparison of CAC with a "sub- groups; however, actual data suggest that relative benefit is in fact highest in the lowest risk categories (11) . The same could be true across CAC strata.
For CAC scoring or other markers, including the new equations, to achieve Class I (or III) recommendations in clinical guidelines, all these questions will need to be addressed in a properly designed, prospective, randomized clinical trial. We therefore join our voice to that of the authors and others (12, 13) encouraging the National Institutes of Health, perhaps in partnership with industry, to lead this effort. Although such an enterprise will undoubtedly Coronary Calcium Score and the New Guidelines O C T O B E R 1 3 , 2 0 1 5 : 1 6 6 9 -7 1 be daunting and costly, will not be perfect, and will not provide all answers, few prevention trials could have a broader impact on the population at large.
Alternatively, we can continue to speculate, assume, and extrapolate.
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